Overview

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Status:
Not yet recruiting
Trial end date:
2027-01-15
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of Almonertinib versus placebo following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).
Phase:
Phase 3
Details
Lead Sponsor:
Jiangsu Hansoh Pharmaceutical Co., Ltd.